Shelley Brunkan, PA-C
Physician Assistant · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Shelley Brunkan’s office at (650) 723-4000 to ask if they take your plan before you enroll.
California Medical Board record
Licence G63239 · Current
Licensed to practise in California · since 1988 · expires 2028-02-29 · University of Arkansas College of Medicine.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Original Medicare doctor bills
$1,378,356
Medicare paid this office $1,378,356 for 210 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, pembrolizumab, 1 mg | 13 | $312,901 | None |
| Injection, denosumab, 1 mg | 19 | $60,321 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 22 | $30,075 | None |
| Return visit (30+ min) | 92 | $18,645 | $104 |
| Long return visit (40+ min) | 66 | $16,584 | $145 |
See all 22 services
| Injection, pembrolizumab, 1 mg | 13 | $312,901 | None |
| Injection, denosumab, 1 mg | 19 | $60,321 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 22 | $30,075 | None |
| Return visit (30+ min) | 92 | $18,645 | $104 |
| Long return visit (40+ min) | 66 | $16,584 | $145 |
| Administration of chemotherapy into vein, 1 hour or less | 50 | $16,487 | $119 |
| Short return visit (20+ min) | 52 | $6,760 | $74 |
| Injection of additional new drug or substance into vein | 39 | $3,100 | $14 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 11 | $2,892 | $0 |
| Administration of additional new drug or substance into vein, 1 hour or less | 17 | $2,771 | $58 |
| Injection of drug or substance under skin or into muscle | 56 | $1,400 | $12 |
| Administration of chemotherapy into vein, each additional hour | 17 | $1,337 | $24 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 31 | $1,150 | $25 |
| Injection of drug or substance into vein | 17 | $789 | $33 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 11 | $681 | $57 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 48 | $677 | $8 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 12 | $628 | $25 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 12 | $616 | $31 |
| Injection, palonosetron hcl, 25 mcg | 24 | $552 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 28 | $66 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 30 | $41 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 11 | $17 | None |
Who their Medicare patients are
210 Original Medicare patients in 2024. Average age 76 · Under 65 6% · 85 and older 18% · Women 51% · Also on Medicaid 16% · Health risk score 2.34. Above the middle of the specialty; the typical physician assistant clinician is at 1.31.
Conditions among them: High blood pressure 75% · Chronic kidney disease 52% · Cancer 47% · Diabetes 34% · Coronary heart disease 30% · COPD 25% · Atrial fibrillation 25% · Depression 24% · Heart failure 23% · Stroke 11% · Dementia 8%.
The office billed $6,690,360, Medicare allowed $1,727,010 and paid $1,378,356; for 82,616 services of 101 kinds; $1,300,076 of it was for drugs given in the office and $78,279 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 210 | 82,616 | 76 | 2.34 | $6,690,360 | $1,378,356 |
| 2022 | 11 | 21 | 74 | 2.88 | $10,230 | $1,534 |
| 2020 | 18 | 30 | 70 | 3.89 | $9,245 | $1,496 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2020: 1 service
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $839 | $56 |
Drugs they prescribed that Part D paid
$1,202,727
Pharmacies billed $1,202,727 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 4% of their Part D prescriptions (19 of 515) in 2024. Above the middle of the specialty; the typical physician assistant clinician is at 1%.
412 generic and 103 brand-name prescriptions · $1,202,727 in drug cost · 11 antibiotic prescriptions to 11 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Jakafi | 12 | $173,361 | $14,447 |
| Revlimid | 11 | $162,225 | $14,748 |
| Abiraterone Acetate | 26 | $63,055 | $2,425 |
| Eliquis | 19 | $12,085 | $636 |
| Letrozole | 23 | $714 | $31 |
See all 14 drugs
| Jakafi | 12 | $173,361 | $14,447 |
| Revlimid | 11 | $162,225 | $14,748 |
| Abiraterone Acetate | 26 | $63,055 | $2,425 |
| Eliquis | 19 | $12,085 | $636 |
| Letrozole | 23 | $714 | $31 |
| Prochlorperazine Maleate | 41 | $501 | $12 |
| Hydroxyurea | 14 | $347 | $25 |
| Prednisone | 40 | $223 | $6 |
| Warfarin | 13 | $172 | $13 |
| Ondansetron | 26 | $170 | $7 |
| Gabapentin | 15 | $137 | $9 |
| Lidocaine-Prilocaine | 12 | $136 | $11 |
| Allopurinol | 12 | $95 | $8 |
| Potassium Chloride | 17 | $45 | $3 |
Year by year
| 2024 | 515 | 156 | 4% (19) | 20% | $1,202,727 |
| 2022 | 63 | 31 | 18% (11) | None | $2,907 |
| 2021 | 37 | 13 | None | None | $2,296 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
Money from drug and device companies
$55 in 2025
| 2025 | 2 | 2 | None | $55 |
| 2024 | 8 | 13 | None | $385 |
| 2022 | 2 | 2 | None | $193 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| GlaxoSmithKline | Jemperli | $30 | 1 payment
|
| Teleflex | Arrow | $25 | 1 payment
|
See all 2 published payments
| GlaxoSmithKline | Meals · 2025-07-28 | Jemperli | $30 |
| Teleflex | Meals · 2025-06-25 | Arrow | $25 |
See earlier years (2024, 2022)
2024: $385
| Daiichi Sankyo | Enhertu | $136 | 3 payments
|
| Merck Sharp & Dohme | Keytruda | $59 | 2 payments
|
| Celgene | Pomalyst | $52 | 2 payments
|
| Eisai | Lenvima | $42 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $26 | 1 payment
|
| Lilly USA | Verzenio | $26 | 1 payment
|
| Pfizer | Inlyta | $25 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $20 | 1 payment
|
2022: $193
| Sobi | Doptelet | $115 | 1 payment
|
| G1 Therapeutics | Cosela | $77 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 89.6 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1508416207
- Licence
- CA 63239California G63239: Current · expires 2028-02-29
More record details
- Sole proprietor
- Yes
- Taxonomy
- Physician assistant (363A00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2019-09-14
- NPI last updated
- 2025-05-14
- NPI record certified
- 2025-05-14
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 5725 W Las Positas Blvd Ste 100a, Pleasanton, CA, 94588 · 227 Giddings Ct, San Jose, CA, 95139